SCHEDULE 13G/A 0001104659-24-047308 0001346824 XXXXXXXX LIVE 2 Common Stock, $0.0001 par value per share 12/31/2025 0001824893 Surrozen, Inc. 86889P208 171 OYSTER POINT BLVD SUITE 400 SOUTH SAN FRANCISCO CA 94080 Rule 13d-1(c) RA Capital Management, L.P. DE 0.00 871731.00 0.00 871731.00 871731.00 9.2 IA PN Peter Kolchinsky X1 0.00 871731.00 0.00 871731.00 871731.00 9.2 HC IN Rajeev Shah X1 0.00 871731.00 0.00 871731.00 871731.00 9.2 HC IN RA Capital Healthcare Fund, L.P. DE 0.00 871731.00 0.00 871731.00 871731.00 9.2 PN Surrozen, Inc. 171 OYSTER POINT BLVD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080. The names of the persons filing this report (collectively, the "Reporting Persons") are: RA Capital Management, L.P. ("RA Capital") Peter Kolchinsky Rajeev Shah RA Capital Healthcare Fund, L.P. (the "Fund") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. The address of the principal business office of each of the Reporting Persons is: c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116 RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens. Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. The Fund directly holds (i) Series A warrants (the "Series A Common Warrants") exercisable for up to 322,580 shares of Common Stock, (ii) Series B warrants (the "Series B Common Warrants") exercisable for up to 350,876 shares of Common Stock, and (iii) Series E warrants (the "Series E Common Warrants" and, together with the Series A Common Warrants and Series B Common Warrants, the "Warrants") exercisable for up to 198,275 shares of Common Stock. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's portfolio, including the shares of the Issuer's Common Stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Such percentage is based upon the sum of (i) 8,571,421 shares of the Issuer's Common Stock outstanding as of November 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 7, 2025, (ii) 40,000 shares of Common Stock that were issued upon the exercise of Pre-funded Warrants by the Fund after November 5, 2025, and (iii) 871,731 shares of Common Stock issuable upon exercise of the Warrants. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G/A filed on May 15, 2025) RA Capital Management, L.P. /s/ Peter Kolchinsky 02/17/2026 Peter Kolchinsky /s/ Peter Kolchinsky 02/17/2026 Rajeev Shah /s/ Rajeev Shah 02/17/2026 RA Capital Healthcare Fund, L.P. /s/ Peter Kolchinsky 02/17/2026